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Aggressive natural killer cell leukemia is an extraordinary rare aggressive malignant neoplasm of natural killer cells.
Although its first recognition as a specific entity was approximately 20 years ago, this leukemia has not yet been
satisfactorily characterized as fewer than 200 cases have been reported in the literature and up to our knowledge,
this is the first case report in Qatar. Reaching a diagnosis of aggressive natural killer leukemia was a challenging
experience, because in addition to being a rare entity, the relative scarcity of circulating neoplastic cells, failure to
obtain an adequate aspirate sample sufficient to perform flow cytometric analysis, together with the absence of
applicable method to prove NK clonality (as it lack specific clonal marker); our case had atypical confusing presentation
of striking increase in bone marrow fibrosis that was misleading and complicated the case further. The bone marrow
fibrosis encountered may be related to the neoplastic natural killer cells’ chemokine profile and it may raise the
awareness for considering aggressive natural killer leukemia within the differential diagnosis of leukemia with
heightened marrow fibrosis.
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Aggressive NK- cell leukemia (ANKL) is an extraordinary
rare lymphoproliferative disorder that was first described
by Fernandez et al. (Fernandez et al. 1986). Imamura et al.
(Imamura et al. 1990) also identified leukemia of NK-cell
origin, but their findings were not published for several
years. The World Health Organization Classification first
recognized its aggressive clinical behavior and separated
it from T-cell large granular lymphocyte leukemia, calling
it Aggressive NK-cell Leukemia in 2001 (Chan et al.
2001). This entity is characterized by systemic neoplas-
tic proliferation of NK-cells, almost always associated
with Epstein-Barr virus, detected most reliably by in
situ hybridization (ISH) for EBV-encoded RNA (EBER),
constituting a diagnostic requisite. ANKL occurs at a
relatively young age group with a median age of 42 years
and strong racial predisposition as it is most prevalent
among Asians (Imamura et al. 1990). The patients usually* Correspondence: dsoliman@hmc.org.qa
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in any medium, provided the original work is ppresent with poor general condition, fever, and dissemi-
nated disease with rapidly progressive clinical course
(Chan et al. 1997), they often die within a short time from
systemic disease or complications such as multi-organ
failure (Chan et al. 2008). Since the number of neoplastic
cells in the peripheral blood and bone marrow can be
limited compared to the usual leukemia, this disease also
has been called aggressive NK-cell leukemia/lymphoma
(Chan 1998). The neoplastic cells are typically CD2+,
surface CD3-, cytoplasmic CD3ε+, CD56+ with germline
configurations of T-cell receptor genes and expression of
cytotoxic molecules (perforin, granzyme B, and TIA-1)
(Chan et al. 2008; Chan et al. 2010). According to WHO
(2008), NK cell neoplasms include: chronic lymphopro-
liferative disorder of NK cells (CLPD-NK) (a provisional
entity) and the malignant subtypes including extranodal
NK/T-cell lymphoma of the nasal type (ENKL) and aggres-
sive natural killer leukemia (ANKL) (Chan et al. 2008). The
first entity (CLPD-NK) is more indolent compared to
fulminating prognostically adverse extranodal NK/T-cell
lymphoma of the nasal type (ENKL) and aggressive natural
killer leukemia (ANKL). Immunophenotypically, the latteran Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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(FSC) and usually more CD7 negative and CD16 negative,
compared to the former subtype which is CD56 dim/nega-
tive CD16 positive (Jiang et al. 2013; Trotta et al. 2005).
However, all of them are associated with EBV infection
(Chan et al. 2008; Nava & Jaffe 2005). CD56 is a neural cell
adhesion molecule, it is a sensitive marker for NK cells, as
it is expressed very early on committed NK precursors and
on more than 95% of mature NK cells; its strong expression
is related to the invasion and poor prognosis of neoplasms
(Kwong et al. 1997).
Case report
A 49-year-old Philipino male, not known to have any
chronic illness, was admitted in April 2013 in the depart-
ment of medicine with a two-month history of weight loss,
epigastric pain along with loss of appetite, easy fatigability
and two days history of fever.
On physical examination, the patient was pale, jaun-
diced with a very poor general condition (performance
status 3) and no apparent skin lesions. He was febrile with
temperature of 39°C, pulse 100/min and blood pressure of
100/60 mmHg.
The patient’s laboratory work-up revealed markedly
raised total bilirubin at 101umol/L (n: 3.5-24) with direct
fraction of 57 umol/L, low Albumin 29 g/L (n: 35–50),
slightly elevated ALT 45 U/L (n: 0–40), normal total pro-
tein, AST, Alkaline Phosphatase, Creatinine, electrolytes
and normal B12/folate.
Coagulation screening revealed progressively prolonged
APTT with normal PT, increased D-Dimer of 4.8 mg/L
(n: up to 0.55 mg/L EFU) and low protein C (46%)
(n: 70-140%).
His CBC parameters showed pancytopenia with hemo-
globin of 8.8 g/dl (n: 13–17), mild reticulocytosis at
5%, mildly reduced WBC 2.5 ×10/ul (n: 4–10), mild
neutropenia (absolute neutrophil count of 1.8 ×103/ul
(n: 2–7), and marked thrombocytopenia of 20 ×103/ulA
Figure 1 Morphology of neoplastic cells. (A) Composite showing examp
obtained from subsequent peripheral blood smears. (B) Bone marrow aspir
megakaryocyte with multiple widely separated nuclei) (Lower left corner).(n: 150–400). Serum level of lactate dehydrogenase was un-
expectedly within normal 233U/L. Septic workup includ-
ing blood, urine, stool and ascitic fluid culture revealed
Klebsiella pneumoniae septicemia.
At presentation, peripheral blood smear showed mild
polychromasia, few elliptocytes and rare tear drops. The
majority of circulating lymphocytes were small and
mature with very rarely encountered atypical-primitive
looking lymphoid cells (Figure 1A).
Viral serology disclosed heavy infection with Epstein-Barr
virus with (EBV) DNA of 26,754 copies/ml by PCR with
positivity for Hepatitis B surface antigen, Hepatitis B
core antibody and no detectable Hepatitis B virus DNA.
Hepatitis C, HIV and HTLV antibody were all negative.
Whole body CT scan revealed bilateral pleural effusion,
ascites with minimal pericardial effusion, MRI of the
abdomen showed hepatomegaly, splenomegaly; multiple
enlarged lymph nodes noted in the inguinal, retroperiton-
eal, porta hepatis, mesenteric and paraaortic regions, the
largest lymph nodes were at the porta hepatis.
Bone marrow examination was then performed; the
aspirate smear was partially hemodilute, infiltrated with
primitive looking lymphoid cells comprising approximately
of 22%, of medium to large size with blastoid dispersed
chromatin, prominent multiple small nucleoli and abun-
dant moderately basophilic cytoplasm. Fine cytoplasmic
granulations were noted in few neoplastic cells. Erythropoi-
esis was mildly hyperplastic with some dyserythropoietic
changes, mainly in the form of megaloblastoid chromatin
and nuclear irregularities encountered in about 20% of
erythroid precursors. No significant dysgranulopoietic
changes were noted. Examination of bone marrow biopsy
revealed hypercellular marrow with few necrotic areas;
that is extensively infiltrated with atypical lymphoid
cells with round or irregular nuclei, rather condensed
chromatin, multiple small nucleoli residing within a
reactive inflammatory back ground composed of small
lymphocytes, histiocytes, neutrophils, eosinophils, andB
les of pleomorphic circulating leukemic cells in peripheral blood
ate smear showing four blastoid looking cells (arrows) and dysplastic
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striking megakaryocytic hyperplasia with some clustering,
marked atypia in the form of abnormal separation of
nuclear lobes with evident anisocytosis and some micro-
megakaryocytes (Figure 3). The dysplastic megakaryocytes
were also present in the aspirate smear, however, their
percentage cannot be determined due to insufficient
aspiration material obtained (Figure 1B).
By immunohistochemical stains, the abnormal cells were
strongly positive for CD3 epsilon (CD3ε polyclonal, Dako,
Denmark), CD56 and EBV RNA (using ISH technique)
(Figure 4) and negative for CD20, CD5, CD4 & CD8 with
partial weak positivity for CD7. The percentage of infiltra-
tion was approximately 60-80%.
Reticulin stain highlighted diffuse increase in reticu-
lin fibrosis with some intersections (grade II out of III)
(Figure 2C) and focal bundles of collagen deposition
highlighted by Trichrome stain (Figure 2D) associated
with streaming of hemopoietic cells noted in some areas
of bone marrow biopsy.
Cervical lymph node biopsy was inconclusive as it
revealed reactive changes with picture suggestive of
dermatopathic lymphadenopathy and did not raise the
suspicion of involvement by NK malignancy. Flow cytom-
etry performed on lymph node revealed moderate increase
in NK cells. Flow cytometry was then performed on ascitic
fluid using antibody panel: CD45, CD2, sCD3, CD5, CD7,C
A
Figure 2 Bone marrow biopsy findings. (A) Biopsy section (H&E), at low
(B) CD56 immunostain highlighting marked increase in NK cells (50×). (C) R
(D) Trichrome stain highlighting focal bundles of collagen deposition (50×CD4, CD8, CD56, CD57, CD16, TCR alpha-beta and TCR
gamma-delta, it revealed approximately 20% NK-cells
expressing CD2, CD7 & CD56, they were negative for
CD3 (surface), CD4, CD5, CD8, CD57, TCR alpha-beta
and TCR gamma-delta (Figure 5).
In order to R/O nasal or sinus involvement, CT and
MRI head were carried out and it showed clear nasal
passages and paranasal sinuses with no mass lesions.
Conventional Cytogenetic analysis using GTG-banding
was performed on unstimulated 24 and 48 hours culture of
bone marrow aspirate according to standard procedures;
it revealed an abnormal clone with complex karyotype
(≥3 aberrations) consisting of aneuploidy cells with 44, X,
(missing the sex chromosome Y), derivative chromosome
17, derivative chromosome 2 that resulted from reciprocal
translocation between the chromosomes 2 and 10 at
bands q37 and q11.2, respectively, besides an additional
material of unknown origin attached at band p?11.2 in 15
cells (Figure 6). Molecular Cytogenetics (FISH) analysis
was performed using LSI TP53 SO/CEPSG which allows
the distinction of the chromosomes 17 (p53 gene) and MLL
gene (11q23) LSI MLL Dual color, Break Apart Rearrange-
ment probe (Abbott, molecular, Vysis, Des Plaines, IL,
USA). A total of 300 interphase cells and at least seven
abnormal metaphase cells each were analyzed by FISH.
Deletion of the p53 gene was confirmed by FISH in
11% of the nuclei cells analyzed. Interphase nuclei cellsD
B
magnification (20×) showing infiltration by abnormal lymphoid cells.




Figure 3 Megakaryocytic atypia and anisocytosis. (A) Biopsy section (reticulin stain) showing megakaryocytic atypia with small clusters,
(B) CD61 immunostain showing megakaryocytic clustering (10×), (C) CD61 immunostain showing anisocytosis (50×).
A B
DC
Figure 4 Immunohistochemistry performed on bone marrow biopsy section (20×). The lymphoid infiltrate is positive for CD3 (epsilon)
(A), negative for CD5 (B), positive for CD56 (C) positive for EBV (D).
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Figure 5 Flow cytometry performed on ascitic fluid. The population of interest expresses CD2, CD7 and CD56, and lacks surface CD3, CD16,
CD57 and TCR alpha-beta. Abbreviations ECD, phycoerythrin-Texas Red; FTIC, fluorescein isothiocyanate; PE, phycoerythrin.
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was analyzed. During the patient’s stay in the hospital, his
general condition was deteriorated with increase of the
tumor burden, aggravation of ascites, hepatosplenomeg-
ally, and lymphadenopathy along with progressive pan-
cytopenia and increase in the percentage of the abnormal
lymphoid cells in the peripheral smear (Figure 1A).Figure 6 Karyotype by conventional cytogenetics. ISCN:44,X,-Y, der(2) t
metaphases were karyotyped according to the International System for Hu
processing and data were carried out using microscope Zeiss-AX10 scope.ASince admission, the patient was started on supportive
measures including albumin, antibiotics and antiviral
(entecavir 0.5 mg). As the patient developed significant
anemia and thrombocytopenia, he received multiple
packed RBC and platelets transfusion. He developed an
autoimmune hemolytic anemia with strong positivity for
direct coomb’s test (DAT), (++) IgG and reticulocytosis.(2;10) (q37;q11.2), der(17) (p?11.2) (Zhang et al. 2012). A minimum of 20
man Cytogenetic Nomenclature (Shaffer et al. 2009), image capturing,
1 with IKAROS imaging system (Metasystems, Germany).
Soliman et al. SpringerPlus 2014, 3:390 Page 6 of 9
http://www.springerplus.com/content/3/1/390In view of the pathologic findings and the clinical
picture, a diagnosis of aggressive NK cell leukemia was
made. After confirmation of the diagnosis, SMILE protocol
(dexamethasone, methotrexate, ifosfamide, l-asparaginase,
and etoposide) was planned but unfortunately, the patient’s
response could not be monitored as he travelled back to
his home country before initiation of therapy.
Discussion
Aggressive natural killer cell leukemia (ANKL) is a rare
aggressive malignant neoplasm of natural killer cells (NK),
only recently recognized, with a median survival of less
than 2 months (Sokol & Loughran 2006) and a strong
association with the Epstein-Barr virus. Although the
first recognition of ANKL as a specific entity was ap-
proximately 20 years ago, this leukemia has not yet
been satisfactorily characterized as fewer than 200 cases
have been reported in the literature. In flow cytometry
immunophenotyping, the definition of NK cell is the
lymphocyte on which CD3 is negative, CD16 and/or
CD56 are positive. Abnormal NK cells are similar to
normal NK cells in immunophenotype, they express
CD2, CD7, CD11c, CD16, and CD56. CD3 and CD4 are
not expressed in all NK cells (Jiang et al. 2013).
The lack of a uniquely rearranged antigen receptor gene
in natural killer (NK) cells that can be used to detect clonal
cellular expansion has served as a stumbling block in estab-
lishing the presence of NK cell neoplasm. At present, the
identification of abnormal NK cells mostly relies on the
pathological morphology and immunohistochemistry.
Fewer than 100 cases of ANKL were reported in the
English- language literature till 2010 (Gogia et al. 2010)
involving Japanese, Korean, Chinese and Caucasians
patients. 20 more cases were studied in a Chinese study
published in 2012 (Zhang et al. 2012), 3 more Japanese
cases were reported in 2012 (Okuno et al. 2012), one
case was reported in Danish study (Boysen et al. 2011)
and additional 43 cases of ANKL were involved in another
large Chinese study conducted in the time period between
2006–2012 and published in 2013 (Jiang et al. 2013). Up
to our knowledge this is the first case report in Qatar.
In our case the diagnosis was challenging and somewhat
delayed; this was especially caused by lack of sufficient
BM aspiration enough to perform immunophenotyping
by flow cytometry, in addition to the rarity of circulating
neoplastic cells. Furthermore, morphologically, the neo-
plastic cells had a primitive blastoid appearance with no
specific distinguishing features. Unlike NK lymphomas,
with a more mature phenotype, no clear cytoplasmic
granules were detected by light microscopic examination.
Furthermore, the CD3-positive lymphoid infiltrate of the
bone marrow biopsy showed interstitial pattern that can
be conceived as an inflammatory infiltrate particularly in
the presence of active EBV viral infection. The strikingfinding was the presence of increased reticulin fibrosis
with rather megakaryocytic atypia, a finding that added
more confusion and complicated the case further.
Disorders associated with increased BM fibrosis includ-
ing primary myelofibrosis were initially considered in the
differential diagnosis especially in view of pancytopenia,
hepatosplenomegally, leucoerythroblastic picture, and
increased blastoid looking cells.
This possibility soon vanished after examination of the
immunostains which highlighted massive interstitial infil-
tration with CD3 positive cells with no increase in CD34
positivity by immunohistochemistry (<1%).
The CD3 used in immunohistochemistry is CD3ε that
is specific for cytoplasmic epsilon chain found in both T
cells and NK cells. The next question was are these true
T cells or NK cells with cytoplasmic CD3 expression?,
the answer came shortly after the second immunohisto-
chemical panel (which included T-cells and NK-cells’
more specific markers), favoring NK cell origin with
negativity for CD5, CD4, CD8, CD57, strong positivity
for CD56+, granzyme B and weak positivity for CD7.
The whole picture was then consistent with NK-cell
neoplasm, however, because of the lack of a hallmark
diagnostic marker, the distinction between this groups of
diseases can be confusing, as they share some pathologic
features and similar immunophenotypes. CLPD-NK was
initially omitted as we did not have persistently increased
NK cells (≥2 × 109/L), a criterion required by the WHO
for this diagnosis. It has been suggested that aggressive
NK-cell leukemia may represent the leukaemic phase of
extranodal NK-T-cell lymphoma, however, there are some
distinctive features for the former: younger median age,
high frequency of hepatosplenic and BM involvement, low
frequency of skin involvement and disseminated disease
(Zhang et al. 2012).
Demonstration of strong EBV positivity by Epstein-Barr
encoding region (EBER) in situ hybridization (EBER-ISH)
was another supporting evidence, it is considered a diag-
nostic requisite as more than 90% of cases harbor EBV,
which occurs in clonal episomal form (Au et al. 2004).
EBV-negative cases should be diagnosed as peripheral T-
cell lymphoma, not otherwise specified (Chan et al. 2008).
Some studies showed that plasma EBV DNA was corre-
lated with tumor load, with high EBV DNA correlating
negatively with survivals (Au et al. 2004). Serial EBV DNA
monitoring is useful for assessing response, detecting
recurrence (Au et al. 2004) and may be useful in risk
stratification for HSCT (Eric & Yok-Lam 2013).
There is controversy about CD16 expression in cases of
ANKL, some studies reported relatively high expression
rate of CD16 up to 75% (Suzuki et al. 2004) and 50%
(Ryder et al. 2007), and others revealed absence (Gogia
et al. 2010) or very low expression rate of CD16 (Jiang
et al. 2013). Anyhow, our case showed no significant
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ascitic fluid.
Unlike previous reports which did not report lymphaden-
opathy (Zhang et al. 2012) or reported it at a low incidence
(Jiang et al. 2013; Ryder et al. 2007; Nakashima et al. 2005),
our case had generalized lymphadenopathy. However, both
the lymph node biopsy and flow cytometry on cervical
lymph node failed to characterize an abnormal phenotype
required to confirm LN involvement with neoplastic
process.
There are no specific recurrent cytogenetic abnormal-
ities have been identified in ANKL, a variety of clonal
cytogenetic abnormalities have been reported such as
del (6) (q21q25) and 11q deletion (Zhang et al. 2012;
Nakashima et al. 2005). Our case harbored a complex
karyotype with P53 deletion and novel t (2; 10) (q37;
q11.2), the latter has not been previously reported in
NK-cell malignancies.
The precise role of the p53 point mutation in ANKL
leukemogenesis remains to be clarified, as there are no
reports correlating p53 mutation in ANKL leukemia
with disease progression (M Yagita et al. 2000).
Some previous reports had largely relied on flow
cytometry to characterize the immunophenotype of the
neoplastic cells in cases of ANKL and found it helpful
in the differential diagnosis of NK cell neoplasms; based
on the immunophenotypic differences among ANKL,
CLPD-NK and normal NK cells (Jiang et al. 2013;
Ryder et al. 2007; Ruskova et al. 2004). This was however,
disagreed by Hongyu Z et al. (Zhang et al. 2012) who had
concluded that flow cytometry was of limited value, as
only two out of 20 ANKL patients had aspirate smears
with sufficient malignant cells enough to confirm the
phenotype by flow cytometry. In our case, bone marrow
sample (although repeated) was consistently suboptimal
for flowcytometric analysis. It is however, worth noting
that relatively late in the course of the disease, NK cell
origin was further supported by flow cytometric analysis
performed on ascitic fluid. Jiang et al. (Jiang et al. 2013),
found that 6 out of 11 patients were diagnosed in the
second or third bone marrow biopsy when the disease
had already progressed. In our case, we believe that the
cause behind suboptimal aspirate sample obtained was
most likely related to extensive bone marrow fibrosis
encountered. However, this finding was not previously
reported as a possible cause for difficult sampling. Few
previous studies reported bone marrow stromal damage
including focal reticulin fibrosis (Ryder et al. 2007). The
striking bone marrow fibrosis noted in our case is far
exceeding what usually seen in other cases of acute
leukemia and up to our knowledge it is not previously
reported in this disease entity. The presence of an asso-
ciated contributing factor, although unlikely cannot be
entirely ruled out.While hemophagocytosis and dyserythropoiesis appear
to be the most commonly reported morphologic abnor-
malities in the bone marrow (Chan et al. 1997; Ryder
et al. 2007). Prominent dysmegakaryopoiesis was rarely
reported in the literature (Ruskova et al. 2004).
Our case was found to be a chronic carrier for hepatitis
B, since hepatitis B virus carrier rates are high in popula-
tions at risk of NK/T-cell lymphoma; it is recommended
that hepatitis B virus testing should be routine and antiviral
prophylaxis administered to carriers during chemotherapy
(Liang et al. 1999). Philipp A. Lang, et al (Lang et al. 2012)
has identified a negative regulatory role for NK cells during
both acute and chronic virus infection which may be linked
to reduced clearance of the virus and predispose to chronic
carrier status.
One reason for the fulminant clinical course and adverse
outcome in ANKL is leukemic infiltration into multiple
organs through a chemokine mediated cell trafficking
(Makishima et al. 2007). Among various chemokine
receptors tested, CXCR1 and CCR5 were simultan-
eously expressed on ANKL cells and the leukaemic cells
showed enhanced chemotaxis towards the chemokines
of these receptors (Kato et al. 1998). Further, the serum
levels of the corresponding chemokines interleukin IL-8,
RANTES, macrophage inflammatory protein (MIP)-1α
and MIP-1β, soluble FasL are significantly elevated in
ANKL patients (Kato et al. 1998). In addition, ANKL cells
were found to express high levels of these chemokines
detected by intracellular staining and RT-PCR (Makishima
et al. 2007). Interaction between these chemokines
produced by hepatocytes and chemokine receptors on
leukaemic cells may play an important role in the
transmigration of tumor cells to hepatocytes (Makishima
et al. 2007) that induces inflammatory environment and
subsequent liver fibrosis. Additionally, chemokines such
as MIP-1, MCP-1, and IL-8 have also been hypothesized
to play key roles in the recruitment of leucocytes to
fibrotic lungs and promotion of the pro-fibrotic envir-
onment therein (Palmqvist et al. 2007). In our opinion, a
similar mechanism of chemokines induced marrow fibro-
sis might be implicated in the pathogenesis of accentuated
bone marrow noted.
In conclusion, early diagnosis of aggressive NK leukemia
remains very difficult, as compared with T or B cells neo-
plasms; the absence of specific receptor gene rearrange-
ment prohibits the recognition and characterization of
NK-lineage malignancies. Although, flow cytometry serves
a reliable tool in differentiation between T cell and NK
cell phenotype, it is often difficult to obtain a satisfactory
marrow sample sufficient to perform the analysis that
permits early diagnosis. In agreement with what have
been reported previously (Zhang et al. 2012). We found
that bone marrow biopsy complemented by immuno-
histochemistry and EBER detection provide the most
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the most important antigens for recognition of NK cells
by immunohistochemistry. It is even suggested that if
only paraffin material is available, the diagnosis of ANKL
can still be made, provided that CD56, EBER, and cyto-
toxic molecules are positive (Chan et al. 2008).
Lymph nodes enlargement is not reported frequently in
this entity, moreover, it appears that the detection of
abnormal NK infiltrate in the lymph node is difficult to
characterize and this may raise a question regarding the ac-
tual involvement of the lymph nodes by the neoplastic cells.
The extensive bone marrow fibrosis encountered in this
case may be related to the neoplastic NK cells’ chemokine
profile and it should raise the awareness for considering
ANKL within the differential diagnosis of leukemia with
heightened marrow fibrosis.
As extensive bone marrow fibrosis is not previously
reported in cases of ANKL, more studies are required to
assess the frequency of this finding and to expose any
possible role that might be played by fibrosis in the
pathogenesis of ANKL and its destructive behavior.
Being an extraordinarily rare entity, as more cases of
aggressive NK leukemia/lymphomas are being reported,
our understanding of the clinical and pathological
spectrum of this fatal malignancy is evolving.
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